FDA Approves a New PARP Inhibitor for BRCA-mutant Breast Cancer

In the midst of Breast Cancer Awareness Month, the US. Food and Drug Administration (FDA) provided good news for the breast cancer community this week when it approved a new breast cancer therapeutic called talazoparib (Talzenna), which targets ADP-ribose polymerase (PARP) proteins. They also approved a test to identify those patients eligible to receive talazoparib: patients with metastatic or locally advanced, HER2-negative breast cancer who have an inherited, cancer-associated BRCA1 or BRCA2 (BRCA1/2) mutation.

Read More

Foti Meets with Israeli President, Discusses Cancer’s Global Impact

On Sunday, Margaret Foti, PhD, MD (hc), chief executive officer of the AACR, met with the president of Israel, Reuven Rivlin, at his residence in Jerusalem.

Foti has had a long, fruitful relationship with the Israeli cancer community. Her meeting with Rivlin and First Lady Nechama Rivlin was coordinated by longtime friend and colleague Miri Ziv, the Director General of the Israel Cancer Association.

Read More

Three New Cancer Treatments Approved by the FDA

Last week saw a flurry of new anticancer therapeutics approved by the U.S. Food and Drug Administration (FDA) for treating several types of cancer. On Monday, Sept. 24, the agency approved the molecularly targeted therapeutic duvelisib (Copiktra) for treating certain patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and for treating certain patients with follicular lymphoma. On Thursday, Sept. 27, it approved another molecularly targeted therapeutic—dacomitinib (Vizimpro)—for treating certain patients with non–small cell lung cancer (NSCLC). Then, on Friday, Sept. 28, it approved the immunotherapeutic cemiplimab-rwlc (Libtayo) for treating certain patients with cutaneous squamous cell carcinoma.

Read More

World Cancer Research Day: New Global Statistics Highlight the Need for Research

Today, September 24, 2018, is World Cancer Research Day. The American Association for Cancer Research (AACR) is proud to join cancer organizations, associations, and researchers from around the world in supporting this global initiative that aims to raise awareness about the importance of cancer research for saving lives.

Read More

AACR Applauds FDA’s New Steps to Address Epidemic of Youth E-cigarette Use

In 2017, electronic cigarettes (e-cigarettes) were the most commonly used tobacco product among high and middle school students. Many public health experts believe that youth use of e-cigarettes has reached an epidemic proportion.

On September 12, 2018, the U.S. Food and Drug Administration (FDA) announced a series of critical and historic enforcement actions related to the sale and marketing of e-cigarettes to kids. This effort included issuing more than 1,300 warning letters and fines to retailers who illegally sold e-cigarette products to minors.

Read More

Recent FDA Approvals Signal More Progress Against Cancer

The past month has seen the U.S. Food and Drug Administration (FDA) expand the use of four anticancer therapeutics, providing new treatment options for patients with four types of cancer. On Aug. 16, 2018, the agency approved the immunotherapeutic nivolumab (Opdivo) for treating certain patients with small cell lung cancer and approved the molecularly targeted therapeutic lenvatinib (Lenvima) for treating certain patients with the most common type of liver cancer, hepatocellular carcinoma.

Read More

AACR Cancer Progress Report 2018: Harnessing Research Discoveries for Patient Benefit

Today, the American Association for Cancer Research (AACR) released its eighth annual Cancer Progress Report. The report highlights how federally funded research that provides a deep understanding of the complexities of cancer is spurring advances across the clinical cancer care continuum and improving survival and quality of life for people around the world.

Read More

AACR Project GENIE: More Data, More Participants, and More Progress

AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) recently hit another milestone: the public release of a fourth dataset, which comes on the heels of three prior public data releases, an expansion of the number of participating institutions, and a recent publication, which was among the most read articles in JCO Clinical Cancer Informatics in July, according to the publisher.

Read More